Cargando…

Favipiravir: A new and emerging antiviral option in COVID-19

With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against th...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Umang, Raju, Reyma, Udwadia, Zarir F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/
https://www.ncbi.nlm.nih.gov/pubmed/32895599
http://dx.doi.org/10.1016/j.mjafi.2020.08.004
_version_ 1783577941098102784
author Agrawal, Umang
Raju, Reyma
Udwadia, Zarir F.
author_facet Agrawal, Umang
Raju, Reyma
Udwadia, Zarir F.
author_sort Agrawal, Umang
collection PubMed
description With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
format Online
Article
Text
id pubmed-7467067
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74670672020-09-03 Favipiravir: A new and emerging antiviral option in COVID-19 Agrawal, Umang Raju, Reyma Udwadia, Zarir F. Med J Armed Forces India Review Article With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. Elsevier 2020-10 2020-09-02 /pmc/articles/PMC7467067/ /pubmed/32895599 http://dx.doi.org/10.1016/j.mjafi.2020.08.004 Text en © 2020 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.
spellingShingle Review Article
Agrawal, Umang
Raju, Reyma
Udwadia, Zarir F.
Favipiravir: A new and emerging antiviral option in COVID-19
title Favipiravir: A new and emerging antiviral option in COVID-19
title_full Favipiravir: A new and emerging antiviral option in COVID-19
title_fullStr Favipiravir: A new and emerging antiviral option in COVID-19
title_full_unstemmed Favipiravir: A new and emerging antiviral option in COVID-19
title_short Favipiravir: A new and emerging antiviral option in COVID-19
title_sort favipiravir: a new and emerging antiviral option in covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/
https://www.ncbi.nlm.nih.gov/pubmed/32895599
http://dx.doi.org/10.1016/j.mjafi.2020.08.004
work_keys_str_mv AT agrawalumang favipiraviranewandemergingantiviraloptionincovid19
AT rajureyma favipiraviranewandemergingantiviraloptionincovid19
AT udwadiazarirf favipiraviranewandemergingantiviraloptionincovid19